# Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

> **NCT02962895** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 190 (actual)

## Conditions studied

- Primary Sjogren Syndrome

## Interventions

- **BIOLOGICAL:** VAY736
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02962895
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-27
- **Primary completion:** 2020-06-30
- **Final completion:** 2021-09-23
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02962895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02962895, "Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02962895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*